京新药业(002020)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

002020 京新药业

已收盘 12-15 15:00:00

{"stockData":{"symbol":"002020","market":"SZ","secType":"STK","nameCN":"京新药业","latestPrice":19.42,"timestamp":1765782237000,"preClose":19.16,"halted":0,"volume":10179661,"delay":0,"changeRate":0.0136,"floatShares":724000000,"shares":861000000,"eps":0.8276,"marketStatus":"已收盘","change":0.26,"latestTime":"12-15 15:00:00","open":19.16,"high":19.67,"low":19.06,"amount":198000000,"amplitude":0.0318,"askPrice":19.42,"askSize":67,"bidPrice":19.4,"bidSize":7,"shortable":0,"etf":0,"ttmEps":0.8276,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765848600000},"marketStatusCode":5,"adr":0,"adjPreClose":19.16,"symbolType":"stock","openAndCloseTimeList":[[1765762200000,1765769400000],[1765774800000,1765782000000]],"highLimit":21.08,"lowLimit":17.24,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":861029140,"isCdr":false,"pbRate":2.92,"roa":"--","peRate":23.465442,"roe":"10.1%","epsLYR":0.83,"committee":-0.377176,"marketValue":16721000000,"turnoverRate":0.0141,"status":0,"floatMarketCap":14059000000},"requestUrl":"/m/hq/s/002020/wiki","defaultTab":"wiki","newsList":[{"id":"2590592531","title":"京新药业：LP（a）机制降脂新药对外授权进展中","url":"https://stock-news.laohu8.com/highlight/detail?id=2590592531","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590592531?lang=zh_cn&edition=full","pubTime":"2025-12-11 18:21","pubTimestamp":1765448474,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)12月11日在投资者关系平台上答复投资者关心的问题。投资者提问：问公司吕董，公司降脂药创新药目前BD谈判到底进展如何？京新药业回复：您好！LP（a）机制降脂新药的对外授权工作进展中，公司会努力推进，若有进展敬请关注相关公告。谢谢!以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121100030802.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2590592537","title":"京新药业：在精神分裂细分适应症上做差异化布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2590592537","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590592537?lang=zh_cn&edition=full","pubTime":"2025-12-11 18:21","pubTimestamp":1765448473,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)12月11日在投资者关系平台上答复投资者关心的问题。投资者提问：公司回复说JX11502和盐酸卡利拉嗪都是针对精神分裂适应症，如果没有那为什么要重复研发多花钱做临床试验呢？京新药业回复：您好！公司会在精神分裂细分适应症上做差异化布局。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121100030801.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2589532873","title":"京新药业：地达西尼销售正常推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2589532873","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589532873?lang=zh_cn&edition=full","pubTime":"2025-12-07 11:51","pubTimestamp":1765079468,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)12月07日在投资者关系平台上答复投资者关心的问题。投资者提问：问公司吕董，公司新药地达西尼进入四季度后销售增速还象三季度吗？降脂新药CBD业务进展如何？京新药业回复：您好!公司治疗失眠的1类新药地达西尼目前销售正常推进中，公司会做好入院工作，争取实现更好的销售业绩。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120700001370.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2589873872","title":"京新药业：JX11502和盐酸卡利拉嗪均针对精神分裂适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2589873872","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589873872?lang=zh_cn&edition=full","pubTime":"2025-12-07 11:42","pubTimestamp":1765078932,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)12月07日在投资者关系平台上答复投资者关心的问题。投资者提问：公司JX11502和盐酸卡利拉嗪的适应症完全一致吗？或者有什么区别？谢谢！京新药业回复：您好！公司JX11502和盐酸卡利拉嗪都是针对精神分裂适应症。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120700001366.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2589875873","title":"京新药业：做好沙溪凉茶销售工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2589875873","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589875873?lang=zh_cn&edition=full","pubTime":"2025-12-07 11:42","pubTimestamp":1765078931,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)12月07日在投资者关系平台上答复投资者关心的问题。投资者提问：问公司吕董，公司近几个月就没有公司调研吗？公司新药推广会一般采用什么方式？这么多好药，公司推介为什么跟不上？最近滚感全球流行，公司沙溪制药的沙溪凉荼几百年前就能力可各类流感瘟疫。现在为什么不大力推广？京新药业回复：您好！谢谢您的建议。公司会做好沙溪凉茶的销售工作，让更多人了解其疗效。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120700001365.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2586207958","title":"京新药业：盐酸卡利拉嗪胶囊已提交上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2586207958","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586207958?lang=zh_cn&edition=full","pubTime":"2025-11-28 16:54","pubTimestamp":1764320062,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业11月28日在投资者关系平台上答复投资者关心的问题。是否存在发补或二次资料提交？若达到 5 亿元销售额，预计可贡献多少净利京新药业回复：您好！盐酸卡利拉嗪胶囊已经提交了上市申请，正常推进中。若后续顺利获批，商业化策略会根据产品本身的特点，并借鉴地达西尼的销售经验来推进。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112800023571.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2586920207","title":"京新药业：LP（a）降脂创新药临床I期接近尾声","url":"https://stock-news.laohu8.com/highlight/detail?id=2586920207","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586920207?lang=zh_cn&edition=full","pubTime":"2025-11-28 16:45","pubTimestamp":1764319518,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)11月28日在投资者关系平台上答复投资者关心的问题。投资者提问：今天市场传闻公司的P（a）小分子抑制剂一期实验数据不理想，是不是？目前公司也没有公布临床实验情况怎样？京新药业回复：您好！公司的LP（a）降脂创新药临床I期接近尾声，具体情况敬请关注定期报告。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112800022490.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","002020","BK1161","159992","BK0239","06978"],"gpt_icon":0},{"id":"2584260154","title":"异动快报：京新药业（002020）11月18日9点54分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2584260154","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584260154?lang=zh_cn&edition=full","pubTime":"2025-11-18 09:55","pubTimestamp":1763430928,"startTime":"0","endTime":"0","summary":"证券之星11月18日盘中消息，9点54分京新药业触及涨停板。目前价格20.48，上涨5.73%。其所属行业化学制药目前下跌。领涨股为海南海药。该股为阿尔茨海默病，创新药，化学原料药概念热股，当日阿尔茨海默病概念上涨0.1%。11月17日的资金流向数据方面，主力资金净流入2178.06万元，占总成交额3.28%，游资资金净流出828.77万元，占总成交额1.25%，散户资金净流出1349.28万元，占总成交额2.03%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111800008778.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2584673889","title":"股市必读：京新药业（002020）11月17日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2584673889","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584673889?lang=zh_cn&edition=full","pubTime":"2025-11-18 01:25","pubTimestamp":1763400316,"startTime":"0","endTime":"0","summary":"截至2025年11月17日收盘，京新药业报收于19.37元，上涨4.2%，换手率4.67%，成交量33.84万手，成交额6.65亿元。投资者： 请问10月31日的股东人数多少，谢谢董秘： 您好，公司会在定期报告中披露报告期末的股东人数信息。对于非定期报告的股东人数，股东可向公司董秘办提供股东证明，经核实后予以提供。当日关注点来自交易信息汇总：11月17日主力资金净流入2178.06万元，显示主力对京新药业的积极介入。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111800000906.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2583047933","title":"股市必读：京新药业（002020）11月12日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2583047933","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583047933?lang=zh_cn&edition=full","pubTime":"2025-11-13 03:09","pubTimestamp":1762974557,"startTime":"0","endTime":"0","summary":"截至2025年11月12日收盘，京新药业报收于18.45元，上涨0.99%，换手率1.28%，成交量9.25万手，成交额1.71亿元。投资者： 问公司吕董，新药地达西尼截止11月初共计入院多少家？上半年地达西尼已累计实现医院覆盖数量达1500多家，公司在持续推进地达西尼的入院工作，提高患者的可及性。况且公司产品众多，我看主要还是公司故意压制公司董秘： 您好！当日关注点来自交易信息汇总：11月12日主力资金净流入1248.44万元，显示主力对京新药业的积极介入。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300003169.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2582263653","title":"京新药业：地达西尼已覆盖1500多家医院","url":"https://stock-news.laohu8.com/highlight/detail?id=2582263653","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582263653?lang=zh_cn&edition=full","pubTime":"2025-11-12 16:30","pubTimestamp":1762936259,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)11月12日在投资者关系平台上答复投资者关心的问题。投资者提问：问公司吕董，新药地达西尼截止11月初共计入院多少家？现在平均每月入院大约多少家？京新药业回复：您好！上半年地达西尼已累计实现医院覆盖数量达1500多家，公司在持续推进地达西尼的入院工作，提高患者的可及性。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111200025706.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2582581817","title":"股市必读：京新药业（002020）11月7日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2582581817","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582581817?lang=zh_cn&edition=full","pubTime":"2025-11-10 02:06","pubTimestamp":1762711577,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘，京新药业报收于18.02元，下跌0.72%，换手率1.06%，成交量7.68万手，成交额1.39亿元。董秘最新回复投资者： 盐酸卡利拉嗪片获批后，按有关规定，明年能否进入国家医保目录？公司的盐酸卡利拉嗪已申报待批准。扩大知名度董秘： 您好！当日关注点来自交易信息汇总：11月7日主力资金净流出674.46万元，游资资金净流入1056.54万元，显示市场短期博弈特征明显。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111000000826.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2581793420","title":"京新药业：盐酸卡利拉嗪已申报待批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2581793420","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581793420?lang=zh_cn&edition=full","pubTime":"2025-11-07 15:09","pubTimestamp":1762499357,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)11月07日在投资者关系平台上答复投资者关心的问题。投资者提问：盐酸卡利拉嗪作为购买了原研专利许可销售的国内首仿药，在获批上市后，是否可以进入国家医保目录？谢谢！京新药业回复：您好！公司的盐酸卡利拉嗪已申报待批准。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110700018485.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2581079329","title":"京新药业：地达西尼销售工作正常进行中","url":"https://stock-news.laohu8.com/highlight/detail?id=2581079329","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581079329?lang=zh_cn&edition=full","pubTime":"2025-11-07 15:09","pubTimestamp":1762499357,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)11月07日在投资者关系平台上答复投资者关心的问题。投资者提问：问公司吕董，公司目前两大重磅单品地达西尼和盐酸卡利拉嗪都有顶峰冲击几十亿销售额的大品种，不要说普通患者不知道，做为部分中小投资者都不太清楚，问公司是怎么推介的？京新药业回复：您好！地达西尼的销售工作在正常进行中，公司会做好入院工作和学术推广活动，提高患者的可及性，为患者带来新的治疗解决方案。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110700018487.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2580293319","title":"京新药业：集采中标后积极推动销售提升份额","url":"https://stock-news.laohu8.com/highlight/detail?id=2580293319","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580293319?lang=zh_cn&edition=full","pubTime":"2025-11-03 17:36","pubTimestamp":1762162566,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)11月03日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司在国家医药集采政策中中标之后，是否出现盈利空间受限之类的情况？上下游的付款期限是否会因此受到影响？京新药业回复：您好!首次参加集采的品种，价格会有所下降。但公司的产品集采中标之后，积极推动销售工作，获得更多的销量，努力提升市场份额。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110300024506.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2580539293","title":"京新药业：地达西尼前三季度销售额过亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2580539293","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580539293?lang=zh_cn&edition=full","pubTime":"2025-11-03 17:33","pubTimestamp":1762162389,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)11月03日在投资者关系平台上答复投资者关心的问题。投资者提问：问吕董，公司新药地达西尼前三季度总销售额是多少？计划明年销售额是多少？另公司新药盐酸卡利拉嗪申请到什么程度了，和药监局沟通几次了？以及减脂新药BD到什么程度了？京新药业回复：您好！公司的1类新药地达西尼2025年前三季度累计销售额已经过亿。盐酸卡利拉嗪审批进行中，公司会积极跟监管部门沟通，做好上市的准备工作。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110300024243.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2579906453","title":"京新药业涨7.05%，开源证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2579906453","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579906453?lang=zh_cn&edition=full","pubTime":"2025-10-31 16:26","pubTimestamp":1761899206,"startTime":"0","endTime":"0","summary":"今日京新药业涨7.05%，收盘报18.84元。2025年8月28日，开源证券研究员余汝意,刘艺发布了对京新药业的研报《公司信息更新报告：创新药持续放量，在研管线稳步推进》，该研报对京新药业给出“买入”评级。研报中预计公司2025-2027年归母净利润为8.22、9.53及11.06亿元，EPS为0.95元、1.11元和1.29元，当前股价对应PE为20.0、17.2以及14.9倍，维持公司“买入”评级。此外，中银证券研究员刘恩阳，西南证券研究员杜向阳近期也对该股发布了研报，同样给出“买入”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100033796.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","161027"],"gpt_icon":0},{"id":"2579176813","title":"股市必读：京新药业三季报 - 第三季度单季净利润同比增长8.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579176813","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579176813?lang=zh_cn&edition=full","pubTime":"2025-10-31 02:58","pubTimestamp":1761850693,"startTime":"0","endTime":"0","summary":"股本股东变化股东户数变动截至2025年9月30日，公司股东户数为2.23万户，较6月30日减少3358.0户，减幅为13.08%。业绩披露要点财务报告2025年前三季度，公司主营收入30.48亿元，同比下降5.0%；归母净利润5.76亿元，同比上升0.1%；扣非净利润5.38亿元，同比上升8.92%。2025年第三季度，单季度主营收入10.32亿元，同比下降2.57%；单季度归母净利润1.88亿元，同比上升8.59%；单季度扣非净利润1.78亿元，同比上升11.3%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100003143.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020"],"gpt_icon":0},{"id":"2579187693","title":"图解京新药业三季报：第三季度单季净利润同比增长8.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579187693","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579187693?lang=zh_cn&edition=full","pubTime":"2025-10-30 02:55","pubTimestamp":1761764115,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业2025年三季报显示，前三季度公司主营收入30.48亿元，同比下降5.0%；归母净利润5.76亿元，同比上升0.1%；扣非净利润5.38亿元，同比上升8.92%；其中2025年第三季度，公司单季度主营收入10.32亿元，同比下降2.57%；单季度归母净利润1.88亿元，同比上升8.59%；单季度扣非净利润1.78亿元，同比上升11.3%；负债率28.74%，投资收益1668.74万元，财务费用-3600.35万元，毛利率50.07%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000002934.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020"],"gpt_icon":0},{"id":"2578933557","title":"京新药业：沙溪凉茶具清热除湿导滞功效","url":"https://stock-news.laohu8.com/highlight/detail?id=2578933557","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578933557?lang=zh_cn&edition=full","pubTime":"2025-10-28 16:42","pubTimestamp":1761640930,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)10月28日在投资者关系平台上答复投资者关心的问题。投资者提问：问公司吕董，近期南方流感大面积流行，而公司沙溪制药的沙溪凉茶已有几百年的治流感历史，请问公司吕董并购几年来目前销售增长明显吗？为什么公司不大力推介。京新药业回复：您好！沙溪凉茶是公司的中药品种，具有清热，除湿，导滞的功效。可用于四时感冒，身倦骨痛，寒热交作，胸膈饱滞，痰凝气喘。公司会做好宣传推广工作，希望给患者提供更多的用药选择。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800029127.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765804314243,"stockEarnings":[{"period":"1week","weight":0.0042},{"period":"1month","weight":0.0385},{"period":"3month","weight":-0.0254},{"period":"6month","weight":0.3579},{"period":"1year","weight":0.4324},{"period":"ytd","weight":0.5354}],"compareEarnings":[{"period":"1week","weight":-0.0034},{"period":"1month","weight":-0.0277},{"period":"3month","weight":0.0048},{"period":"6month","weight":0.1517},{"period":"1year","weight":0.1236},{"period":"ytd","weight":0.1604}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江京新药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"22318人(较上一季度减少86.05%)","perCapita":"0股","listingDate":"2004-07-15","address":"浙江省绍兴市新昌县羽林街道新昌大道东路800号","registeredCapital":"86102万元","survey":"　　浙江京新药业股份有限公司的主营业务是化学制剂、传统中药、生物制剂、化学原料药、医疗器械的研发、生产及销售。公司的主要产品是化学制剂、传统中药、生物制剂、化学原料药、医疗器械。公司是第一批“中国医药企业制剂国际化先导企业”，连续多年荣登“中国化学制药行业制剂出口型优秀企业品牌”、“中国医药工业百强”和“中国化学制药企业百强榜”。","listedPrice":10.05},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"京新药业(002020)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供京新药业(002020)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"京新药业,002020,京新药业股票,京新药业股票老虎,京新药业股票老虎国际,京新药业行情,京新药业股票行情,京新药业股价,京新药业股市,京新药业股票价格,京新药业股票交易,京新药业股票购买,京新药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"京新药业(002020)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供京新药业(002020)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}